A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

Article metrics

Abstract

Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds. Thirty-three patients were treated with capecitabine administered orally twice daily on days 1–14, and docetaxel given as a 1 h intravenous infusion on day 1. Treatment was repeated every 3 weeks. The dose of capecitabine ranged from 825 to 1250 mg m−2 twice a day and of docetaxel from 75 to 100 mg m−2. The dose-limiting toxicity (DLT) was asthenia grade 2–3 at a dose of 1000 mg m−2 bid of capecitabine combined with docetaxel 100 mg m−2. Neutropenia grade 3–4 was common (68% of courses), but complicated by fever in only 2.4% of courses. Other non-haematological toxicities were mild to moderate. There was no pharmacokinetic interaction between the two drugs. Tumour responses included two complete responses and three partial responses. Capecitabine 825 mg m−2 twice a day plus docetaxel 100 mg m−2 was tolerable, as was capecitabine 1250 mg m−2 twice a day plus docetaxel 75 mg m−2. © 2000 Cancer Research Campaign

References

  1. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger R, Schachter J, Wanders J, Franklin H and Verweij J (1994) Taxotere in advanced malignant melanoma: a phase II trial of the EORTC Clinical Trials Group. Eur J Cancer 30A: 1061–1064

  2. Aapro MS, Zulian G, Alberto P, Bruno R, Oulid-Aissa D and Le Bail N (1992) Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3 (suppl 5): 208

  3. Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB and Kerr DJ (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523–527

  4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown C and Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493

  5. Ten Bokkel-Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alaki M, Bayssas M and Kaye SB (1994) A phase II trial with docetaxel (Taxotere) in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527–532

  6. Brundage MD, Pater JL and Zee B (1993) Assessing the reliability of two toxicity scales: implications for interpretating toxicity data. J Natl Cancer Inst 85: 1138–1148

  7. Bruno R and Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere. In: Pharmacokinetics and Cancer Chemotherapy, Workman P, Graham MA (eds), pp. 305–313. Cold Spring Harbor Laboratory: New York, NY

  8. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B and Griffin T (1998) Preliminary results of a novel oral fluoropyrimidine carbamate. J Clin Oncol 16: 1795–1802

  9. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, Le Bail N and Von Hoff D (1993) Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion every 3 weeks. J Clin Oncol 11: 950–958

  10. Catimel G, Verweij J, Mattijsen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533–537

  11. Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, Van Meerbeek J, Wanders J, Franklin HR and Kaye S (1994) Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Clinical Trials Group. Br J Cancer 70: 384–387

  12. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, roche H, Krakowski I, Azli N, Bayssas M, Lentz MA and van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314–322

  13. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N and Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037–1042

  14. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R and Verweij J (1997) A randomized phase II study of Xeloda (Capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16: 227a

  15. De Forni M, Rougier P, Adenis A, Ducreux M, Djazouli K, Adams D, Clouet P, Blanc C, Bayssas M, Bonneterre J and Armand JP (1994) Phase II study of Taxotere in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 5 (suppl 5): 509

  16. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Ki Hong W and Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645–651

  17. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L and Poitier P (1991) Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34: 992–998

  18. Hilkens PHE, Verweij J, Stoter G, Vecht Ch, Van Putten WLJ and van den Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46: 104–108

  19. Investigational drug brochure: Capecitabine (Ro 09-1978) Fourth Version, (December 1997).

  20. Van Hoesel QGCM, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, Van Pottelsberghe C, Le Bail N and Mouridsen H for the EORTC Soft Tissue and Bone Sarcoma Group (1994) Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5: 539–542

  21. Ishikawa T, Sawada N, Sekiguchi F, Fukase Y and Ishitsuka H (1997) Xeloda™ (Capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 16: 226a

  22. Khoury P, Villalona-Calero M, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, Von Hoff D and Rowinsky E (1998) Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 17: 206a

  23. Loos WJ, Verweij J, Nooter K, Stoter G and Sparreboom A (1997) Sensitive determination of docetaxel in human plasma by liquid–liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B 693: 437–441

  24. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S and Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977–2985

  25. Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KMW, Venkatraman ES, Woolley K, Heelan RT and Kris MG (1995) Phase II trial of a 75 mg m–2dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 75: 968–972

  26. O’Shaugnessy J, Moiseyenko V, Bell D, Nabholtz JM, Miles D, Gorbunova V, Laws S, Griffin T and Osterwalder B (1998) A randomized phase II study of Xeloda (Capecitabine) vs CMF as first-line chemotherapy of breast cancer in women > 55 years. Proc Am Soc Clin Oncol 17: 103a

  27. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Bayssas MMG and Raber MN (1992) Phase I trial of Taxotere: 5-day schedule. J Natl Cancer Inst 84: 1781–1788

  28. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A and Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer investigational drug branch for breast cancer. J Clin Oncol 15: 3149–3155

  29. Pronk LC, Stoter G and Verweij J (1995) Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev 21: 463–478

  30. Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T and Weidekamm E (1999) Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol, (in press)

  31. Ringel I and Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semisynthetic analog of Taxol. J Natl Cancer Inst 83: 288–291

  32. Rowinsky EK and Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther 52: 35–84

  33. Rowland M and Tozer TN (1995). Clinical pharmacokinetics: concepts and applications, 3rd Edition, Media, Williams and Wilkins

  34. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013–1019

  35. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, Van Oosterom AT and Kaye S (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4: 610–611

  36. Sulkes A, Smyth J, Sessa C, van Oosterom AT, Vermorken J, Kaye SB, Le Bail N and Verweij J for the EORTC Early Clinical Studies Group (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380–383

  37. Taguchi T, Ishitani K, Saitoh K, Kurihara M, Tominaga T, Fukuyama Y, Saigenji K, Toge T, Takashima S, Sugimachi K and Hara Y (1996) A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 7: 87

  38. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M and Klastersky J (1993) Phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458–1467

  39. Twelves C, Budman DR, Creaven PJ, Schellens JHM, Kuruma I, Dumont E, Osterwalder B and Reigner BG (1996) Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 5: 476

  40. WHO (1979). Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication 48: 22–26

Download references

Author information

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Keywords

  • phase I
  • pharmacokinetics
  • capecitabine
  • docetaxel

Further reading